文献速递细菌感染、耐药与抗菌药物医院感染防控新发突发、热带与寄生虫病

COVID-19大流行对抗生素消费和耐药性的影响:跨国生态学研究

A time series analysis approach to quantify change in antibiotic resistance and antibiotic consumption during COVID-19 epidemics: a multicentre cross-national ecological study on behalf of QUantifying change in Antibiotic Resistance, ANTibiotic use, and INfection control during COVID-19 Epidemics study project.
PubMed 文献 · Clin Microbiol Infect · 2025-06-16

该研究采用准实验回顾性多中心生态设计,纳入欧洲和以色列9所大学医院,量化COVID-19大流行期间抗生素消费和耐药菌 Incidence Density 的变化。结果显示大流行对多数中心总抗生素消费有显著影响,广谱抗生素使用增加,耐万古霉素肠球菌等耐药菌 Incidence Density 与大流行强度呈正相关,且各国差异较大。

要点

  • 大流行期间哌拉西林/他唑巴坦、糖肽类和头孢他啶/阿维巴坦处方增加。
  • 6/9中心观察到大流行强度与VRE Incidence Density 正相关,MRSA和CRPA在部分中心亦呈正相关。
  • ESBL-producing E. coli Incidence Density 与大流行强度呈负相关。

核心结论

  • COVID-19大流行与广谱抗生素使用增加和多重耐药菌 Incidence Density 升高相关,且各国变异较大。

研究设计与样本

  • 准实验回顾性多中心生态研究,纳入欧洲和以色列9所大学医院,使用常规产生的回顾性时间序列数据。

主要发现

  • COVID-19大流行对除两个中心外所有中心的总医院抗生素消费有显著影响。
  • 哌拉西林/他唑巴坦、糖肽类和头孢他啶/阿维巴坦处方增加;第三代头孢菌素、大环内酯类和氟喹诺酮类在初始激增后恢复至大流行前水平。
  • 大流行强度与VRE Incidence Density 正相关见于6/9(66%)中心,MRSA-ID和CRPA-ID正相关各见于3/4(44%)中心。
  • ESBL-producing E. coli Incidence Density 与大流行强度呈负相关。

关键数值与推荐

  • 结局包括碳青霉烯耐药鲍曼不动杆菌、碳青霉烯耐药肺炎克雷伯菌、ESBL-producing E. coli、VRE、MRSA、碳青霉烯耐药铜绿假单胞菌和Clostridioides difficile的月度分离株每1000患者日Incidence Density,以及按WHO Access、Watch、Reserve分类的月度AMC。

临床怎么用

  • 结果可支持将AMR作为后COVID-19时代优先事项的国际行动计划。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We aimed to assess the impact of COVID-19 on antibiotic consumption (AMC) and antimicrobial resistance (AMR) in the new epidemiological scenario from a cross-national perspective. METHODS: A quasi-experimental retrospective multicentre ecological study was conducted to explore the impact of COVID-19 on AMC and AMR using routinely generated retrospective time series data. This study included nine Healthcare University Hospitals from Europe and Israel on behalf QUantifying change in Antibiotic Resistance, ANTibiotic use, and INfection control during COVID-19 Epidemics project. Total effects were defined as the difference between the pre-COVID-19 period (ranging from January 2015 or January 2016 to February 2020) and during the COVID-19 pandemic period (March 2020 to July 2021 or December 2021). The outcomes were incidence density (ID) of carbapenem-resistant Acinetobacter baumannii, carbapenem-resistant Klebsiella pneumoniae, extended-spectrum beta-lactamase-producing Escherichia coli, vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus, carbapenem-resistant Pseudomonas aeruginosa and Clostridioides difficile, as monthly isolates per 1000 patient days and the monthly AMC ranked according to the Access, Watch, and Reserve WHO classification system. RESULTS: We assessed 15.9 million total hospital bed days, 315 736 COVID-19 bed days, 52 557 monthly bacterial isolates, and 461 739 monthly antimicrobial defined daily doses. The COVID-19 pandemic had a significant impact on the consumption of overall hospital antibiotics combined in all centres except two. Prescriptions for piperacillin/tazobactam, glycopeptides, and ceftazidime/avibactam increased, whereas third-generation cephalosporins, macrolides, and fluoroquinolones returned to pre-pandemic levels after an initial surge, in all centres. A positive relationship between the pandemic intensity and VRE ID was observed in 6 of 9 (66%) centres followed by methicillin-resistant S. aureus-ID and carbapenem-resistant P. aeruginosa-ID 3 of 4 (44%) for both. A negative relationship was found for extended-spectrum beta-lactamase-producing E. coli ID. DISCUSSION: The COVID-19 pandemic was associated with higher usage of broad-spectrum antibiotics and higher incidence of multidrug-resistant bacteria, with great variability by countries. These results could support international action plans that embed AMR as a priority in the post-COVID-19 era.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Meschiari M, López Lozano JM, Medioli F, et al. A time series analysis approach to quantify change in antibiotic resistance and antibiotic consumption during COVID-19 epidemics: a multicentre cross-national ecological study on behalf of QUantifying change in Antibiotic Resistance, ANTibiotic use, and INfection control during COVID-19 Epidemics study project. Clin Microbiol Infect. 2025. PMID: 40516754. doi:10.1016/j.cmi.2025.06.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。